Medroxyprogesterone acetate in non-metastatic gestational trophoblastic disease

Gary L. Goldberg, Kobus Cloete, Basil Bloch, Klaus Wiswedel, Marco M. Altaras

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The effect of medroxyprogesterone acetate (MPA: Depo-Provera, Upjohn) as a contraceptive agent was assessed in 45 patients with non-metastatic gestational trophoblastic disease and compared with 13 patients using hormonal and 26 patients using non-hormonal methods of contraception. In the whole group of 84 patients 18(21.4%) required chemotherapy. There was no statistically significant difference in the incidence of persistent trophoblastic disease between MPA ( 9 45) and the oral contraceptive group ( 2 13) and MPA and the non-hormonal contraceptive groups ( 7 26).

Original languageEnglish (US)
Pages (from-to)22-25
Number of pages4
JournalBritish Journal of Obstetrics and Gynaecology
Volume94
Issue number1
StatePublished - Jan 1987
Externally publishedYes

Fingerprint

Gestational Trophoblastic Disease
Medroxyprogesterone Acetate
Contraceptive Agents
Oral Contraceptives
Contraception
Drug Therapy
Incidence

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Goldberg, G. L., Cloete, K., Bloch, B., Wiswedel, K., & Altaras, M. M. (1987). Medroxyprogesterone acetate in non-metastatic gestational trophoblastic disease. British Journal of Obstetrics and Gynaecology, 94(1), 22-25.

Medroxyprogesterone acetate in non-metastatic gestational trophoblastic disease. / Goldberg, Gary L.; Cloete, Kobus; Bloch, Basil; Wiswedel, Klaus; Altaras, Marco M.

In: British Journal of Obstetrics and Gynaecology, Vol. 94, No. 1, 01.1987, p. 22-25.

Research output: Contribution to journalArticle

Goldberg, GL, Cloete, K, Bloch, B, Wiswedel, K & Altaras, MM 1987, 'Medroxyprogesterone acetate in non-metastatic gestational trophoblastic disease', British Journal of Obstetrics and Gynaecology, vol. 94, no. 1, pp. 22-25.
Goldberg, Gary L. ; Cloete, Kobus ; Bloch, Basil ; Wiswedel, Klaus ; Altaras, Marco M. / Medroxyprogesterone acetate in non-metastatic gestational trophoblastic disease. In: British Journal of Obstetrics and Gynaecology. 1987 ; Vol. 94, No. 1. pp. 22-25.
@article{605a7258d72f4739bfa90b6ff684c001,
title = "Medroxyprogesterone acetate in non-metastatic gestational trophoblastic disease",
abstract = "The effect of medroxyprogesterone acetate (MPA: Depo-Provera, Upjohn) as a contraceptive agent was assessed in 45 patients with non-metastatic gestational trophoblastic disease and compared with 13 patients using hormonal and 26 patients using non-hormonal methods of contraception. In the whole group of 84 patients 18(21.4{\%}) required chemotherapy. There was no statistically significant difference in the incidence of persistent trophoblastic disease between MPA ( 9 45) and the oral contraceptive group ( 2 13) and MPA and the non-hormonal contraceptive groups ( 7 26).",
author = "Goldberg, {Gary L.} and Kobus Cloete and Basil Bloch and Klaus Wiswedel and Altaras, {Marco M.}",
year = "1987",
month = "1",
language = "English (US)",
volume = "94",
pages = "22--25",
journal = "BJOG : an international journal of obstetrics and gynaecology",
issn = "1470-0328",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Medroxyprogesterone acetate in non-metastatic gestational trophoblastic disease

AU - Goldberg, Gary L.

AU - Cloete, Kobus

AU - Bloch, Basil

AU - Wiswedel, Klaus

AU - Altaras, Marco M.

PY - 1987/1

Y1 - 1987/1

N2 - The effect of medroxyprogesterone acetate (MPA: Depo-Provera, Upjohn) as a contraceptive agent was assessed in 45 patients with non-metastatic gestational trophoblastic disease and compared with 13 patients using hormonal and 26 patients using non-hormonal methods of contraception. In the whole group of 84 patients 18(21.4%) required chemotherapy. There was no statistically significant difference in the incidence of persistent trophoblastic disease between MPA ( 9 45) and the oral contraceptive group ( 2 13) and MPA and the non-hormonal contraceptive groups ( 7 26).

AB - The effect of medroxyprogesterone acetate (MPA: Depo-Provera, Upjohn) as a contraceptive agent was assessed in 45 patients with non-metastatic gestational trophoblastic disease and compared with 13 patients using hormonal and 26 patients using non-hormonal methods of contraception. In the whole group of 84 patients 18(21.4%) required chemotherapy. There was no statistically significant difference in the incidence of persistent trophoblastic disease between MPA ( 9 45) and the oral contraceptive group ( 2 13) and MPA and the non-hormonal contraceptive groups ( 7 26).

UR - http://www.scopus.com/inward/record.url?scp=0023131412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023131412&partnerID=8YFLogxK

M3 - Article

C2 - 2434125

AN - SCOPUS:0023131412

VL - 94

SP - 22

EP - 25

JO - BJOG : an international journal of obstetrics and gynaecology

JF - BJOG : an international journal of obstetrics and gynaecology

SN - 1470-0328

IS - 1

ER -